Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 69.9 kDa. The protein migrates as 35 kDa and 50 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 20 mM HEPES, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human Coagulation factor XI, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
Immobilized Human Coagulation factor XI, His Tag (Cat. No. FXI-H52H5) at 1 μg/mL (100 μL/well) can bind Abelacimab with a linear range of 0.2-8 ng/mL (QC tested).
Immobilized Abelacimab at 1 μg/mL (100 μL/well) can bind Human Coagulation factor XI, His Tag (Cat. No. FXI-H52H5) with a linear range of 2-31 ng/mL (Routinely tested).
Anti-Factor XI Antibody captured on Protein A Chip can bind Human Coagulation factor XI, His Tag (Cat. No. FXI-H52H5) with an affinity constant of 15.2 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Measured by its ability to cleave the fluorogenic peptide substrate, t-butyloxycarbonyl-Ile-Glu-Gly-Arg-7-amido-4-methylcoumarin (Boc-IEGR-AMC). The specific activity is >300 pmol/min/µg (QC tested)
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Factor XI concentrate (factor XI deficiency), CSL Behring | Approved | Csl Behring Llc | Australia | Factor XI Deficiency | Csl Behring Llc | 2014-07-01 | Factor XI Deficiency | Details | ||
Human coagulation Factor XI (LFB) | Approved | Lfb Biotechnologies Sas | Hemoleven | EU | Factor XI Deficiency | Lfb Biotechnologies Sas | 1999-07-01 | Factor XI Deficiency | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Asundexian | BAY-2433334 | Phase 3 Clinical | Bayer AG | Embolism; Myocardial Infarction; Stroke; Thromboembolism; Atrial Fibrillation; Ischemic Attack, Transient; Ischemic Stroke; Hepatic Insufficiency | Details |
Milvexian | BMS-986177; JNJ-70033093; JNJ-3093 | Phase 3 Clinical | Bristol-Myers Squibb Company | Embolism; Renal Insufficiency; Contraception; Acute Coronary Syndrome; Stroke; Thromboembolism; Ischemic Attack, Transient; Atrial Fibrillation; Coronary Thrombosis; Ischemic Stroke; Thrombosis; Kidney Failure, Chronic | Details |
Abelacimab | MAA-868; NOV-12 | Phase 3 Clinical | Novartis Pharma Ag | Pulmonary Embolism; Embolism; Venous Thromboembolism; Neoplasms; Stroke; Thromboembolism; Atrial Fibrillation; Venous Thrombosis | Details |
EP-7041 | EP-7041; HSK36273; HSK-36273; EP7041 | Phase 2 Clinical | Exithera | Blood Coagulation Disorders; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Thromboembolism; Thrombocytopenia; Thrombosis | Details |
Osocimab | BAY-1213790 | Phase 2 Clinical | Bayer AG | Kidney Diseases; Thromboembolism; Kidney Failure, Chronic | Details |
IONIS-FXIRX | FXI-ASO; ISIS-FXIRX; BAY-2306001; IONIS-FXIRX; ISIS-404071; ISIS-416858 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Venous Thromboembolism; Thrombosis | Details |
MK-2060 | MK-2060 | Phase 2 Clinical | Merck Sharp & Dohme Corp | Kidney Diseases; Thromboembolism; Kidney Failure, Chronic; Thrombosis | Details |
REGN7508 | REGN7508 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Venous Thromboembolism | Details |
RBD-4059 | RBD-4059; RBD4059; SR059; SR-059 | Phase 2 Clinical | Suzhou Ribo Life Science Co Ltd | Coronary Artery Disease; Coronary Disease; Venous Thrombosis; Kidney Failure, Chronic | Details |
SHR-2004 | SHR-2004 | Phase 2 Clinical | Beijing Suncadia Medicine Co Ltd | Venous Thromboembolism; Thromboembolism; Dyslipidemias; Atrial Fibrillation; Venous Thrombosis; Thrombosis | Details |
KN-060 | KN-060; KN060 | Phase 2 Clinical | Suzhou Alphamab Co Ltd | Thromboembolism; Obesity; Overweight | Details |
REGN-9933 | REGN-9933 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Venous Thromboembolism | Details |
Ir-CPI | BIOX-101; Ir-CPI | Phase 2 Clinical | Free University Of Brussels | Cerebral Hemorrhage | Details |
Fesomersen | ION-957943; IONIS-FXI-LRx; BAY-2976217 | Phase 2 Clinical | Ionis Pharmaceuticals Inc | Nephrosis; Thromboembolism | Details |
SHR2285 | SHR-2285 | Phase 2 Clinical | Jiangsu Hengrui Medicine Co Ltd | Embolism; Venous Thromboembolism; Thromboembolism; Venous Thrombosis; Thrombosis | Details |
ONO-7269 | ONO-7269 | Phase 1 Clinical | Ono Pharmaceutical Co Ltd | Cerebral Infarction | Details |
BAY-1831865 | AB-012; BAY-1831865 | Phase 1 Clinical | Aronora Inc | Thrombosis | Details |
A-336 | A336; A-336 | Phase 1 Clinical | Klus Pharma | Thromboembolism | Details |
A-186 | A-186 | Phase 1 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Thromboembolism | Details |
BMS-262084 | BMS-262084 | Phase 1 Clinical | Bristol-Myers Squibb Company | Thrombosis | Details |
SRSD-107 | SRSD-107; SRSD107 | Phase 1 Clinical | Sirius Therapeutics Inc | Arterial Thromboembolism; Venous Thromboembolism; Thromboembolism; Cardiovascular Diseases; Thrombosis | Details |
BMS-986209 | BMS-986209 | Phase 1 Clinical | Bristol-Myers Squibb Company | Details | |
NIP-003 | NIP003; NIP-003; CRB4101; CRB-4101 | Phase 1 Clinical | National Institutes Of Pharmaceutical Research And Development Co Ltd | Venous Thromboembolism; Thromboembolism; Venous Thrombosis | Details |
Factor XIa Inhibitor (Bayer) | Factor XIa Inhibitor (Bayer) | Phase 1 Clinical | Bayer AG | Blood Coagulation Disorders | Details |
SKB-336 | SKB-336 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Embolism; Thromboembolism | Details |
SAL-0104 | SAL-0104; SAL0104 | Phase 1 Clinical | Suzhou Genemen Biotech Co Ltd | Embolism; Myocardial Infarction; Venous Thromboembolism; Stroke; Ischemic Attack, Transient; Cardiovascular Diseases; Venous Thrombosis; Thrombosis | Details |
STP122G | STP-122G; STP122G | Phase 1 Clinical | Sirnaomics Biopharmaceuticals (Suzhou) Co Ltd | Embolism and Thrombosis | Details |
This web search service is supported by Google Inc.